Elan Corporation Plc Newswire

Elan Corporation Plc Newswire

Comprehensive Real-Time News Feed for Elan Corporation Plc.

Results 1 - 7 of 7 in Elan Corporation Plc

  1. Twenty years later, the Esperante GTR-1 is still StupefyingRead the original story w/Photo

    Friday Jun 10 | AutoWeek

    At 7000 RPM, conversation is impossible in the one-and-only street-legal Panoz GTR-1. The coupe's carbon-fiber race tub vibrates like a tuning fork.


  2. Deadline Upcoming in Settlement in the Elan Corporation Plc (ADS)...Read the original story w/Photo

    May 13, 2016 | SBWire

    A settlement was reached with the defendants in the lawsuit filed on behalf of certain investors of Elan Corporation plc and Wyeth over alleged securities laws violations and a deadline to submit the settlement claim is upcoming on May 21, 2016 and NYSE: ELN and NYSE: WYE investors should contact the Shareholders Foundation. The Shareholders Foundation announced that a deadline is coming up on May 21, 2016 in the settlement reached in the securities class action lawsuit filed on behalf of investors who purchased shares of Elan Corporation plc and Wyeth between January 14, 2008 and July 18, 2008.


  3. NDA Partners Introduces Medical Device Expert Consulting PracticeRead the original story w/Photo

    May 11, 2016 | PRWeb

    NDA Partners announced today formalization of the firm's long-standing Expert Consultant practice in the area of medical device development and regulation. The medical device team is led by David Feigal, Jr., MD, MPH, a Partner in the company, and includes top-tier Experts Consultants with extensive industry and regulatory agency experience in medical device development and regulation.


  4. Asterias Biotherapeutics Names New CEORead the original story

    Feb 27, 2016 | BioSpace

    In addition, the Company announced the appointment of to its Board of Directors. Mr. Bailey, who previously served as President and Chief Executive Officer of Questcor Pharmaceuticals Inc. until its sale for have superb track records of creating substantial shareholder value over time by building successful, high growth pharmaceutical businesses, advancing products through the development process, and commercializing therapies that address conditions with high unmet therapeutic needs.


  5. Cohen barred from managing investor funds for 2 yearsRead the original story w/Photo

    Jan 9, 2016 | The Echo

    Hedge fund billionaire Steven Cohen was barred from managing outside money through 2018 under a settlement related to insider trading announced Friday by the Securities and Exchange Commission. For Cohen, the longtime focus of a federal insider-trading investigation, the agreement with the Securities and Exchange Commission saves him from a lifetime ban from the industry, an outcome the agency had previously sought.


  6. ABN Fall Networking Event - Tuesday, November 24thRead the original story

    Oct 14, 2015 | Groong

    PRESS RELEASE Armenian Business Network 48 Webster Road Lexington, MA 02421 Contact: Jack Antounian Tel: 617-633-4951 Email: [email protected] Tuesday, November 24, 2015 The Renaissance Boston Waterfront Hotel 606 Congress Street, Boston, MA Registration: 6:30pm - Atlantic Ballroom - 2nd Floor Guest Speaker: 7:00pm Dr. Garo H. Armen - "Improving Self, Society and the Environment" Networking: 8:00pm - Capiz Bar Dear Friends & Colleagues: Join us on Tuesday, November 24th for ABN's Fall Business Networking Event, at the Renaissance Boston Waterfront Hotel, at 6:30pm. We are excited to feature Dr. Garo H. Armen, as the Guest Speaker.


  7. Alzheon Appoints Susan Abushakra, M.D., as Chief Medical OfficerRead the original story

    Sep 9, 2015 | Freshnews

    Alzheon, Inc., a clinical-stage biopharmaceutical company focused on developing new medicines for patients suffering from Alzheimer's disease and other neurological and psychiatric disorders, today announced the appointment of Susan Abushakra, M.D., as Chief Medical Officer. "I am pleased to welcome Susan to the Alzheon team," said Martin Tolar, M.D., Ph.D., Founder, President and Chief Executive Officer of Alzheon.